Health House Holdings Limited is a International distributor of medicinal cannabis and was founded to pursue opportunities in the burgeoning global medicinal cannabis market. Since 2014, the Board and founding shareholders of the Company have been pioneers in the medicinal cannabis sector establishing a number of publicly-listed companies including AusCann Group, Zelda Therapeutics and CannPal Animal Therapeutics.
In March 2019 Health House Holdings Limited acquired Health House International PTY Ltd a business that was granted the first licence in Australia to import and distribute medicinal cannabis. Health House International PTY Ltd is fully operational wholesale distribution business serving the expanding Australian market and is well positioned to expand into New Zealand and South East Asia.
In September 2019 Health House Holdings Limited completed the acquisition of P&D Pharmaceuticals a UK-based, speciality pharmaceutical wholesaler with a 30 years trading history and an experienced operating team.
Now trading as Health House Pharma Limited, the company currently supplies a range of pharmaceutical products to pharmacies, hospitals, government departments, ambulance workers and other wholesalers in the UK and EU. Health House Pharma also owns a specialised UK Pharmacy giving the company the ability to fulfill Cannabis prescriptions directly to a consumer.
The company holds a number of strategic licenses to store, distribute, import, export and wholesale controlled drugs and is well positioned to have an early mover advantage into the UK and European medicinal cannabis market. Health House Pharma Ltd is strategically located close to Heathrow/Gatwick airports allowing it to service all of Europe and UK with next day delivery.
Health House Holdings Limited is building value for its shareholders principally by focusing on the newly legalised medicinal cannabis market in United Kingdom market and newly emerging regulated European & Asia Pacific markets.
Health House Holdings Limited has secured exclusive access to pharmaceutical-grade (EU-GMP) products for the UK, Australia and South-East Asia markets with multiple branding options from 5 major suppliers including HAPA Medical BV – a company building a leading position in the German market.
The future is in the therapeutic use of medicines.
Highly experienced team with networks throughout the medicinal cannabis supply chain.
Proven Track Record
The team have been pioneers in the Australian medicinal cannabis sector establishing a number of publicly-listed companies including AusCann Group, Zelda Therapeutics and CannPal Animal Therapeutics.
License agreements in place for distribution of exclusive branded premium product into specific markets. Early mover advantage into newly emerging markets including the United Kingdom. New opportunities for partnering and value adding being explored.
Premium Product Range
Exclusive access to pharmaceutical-grade (EU-GMP) product for United Kingdom, Australia and South-East Asia markets with multiple branding options. Expanding portfolio of third party products from a variety of suppliers.
Growing Global Market
Rapid growth continues with new federally legal markets opening at an increasing pace
Well established networks in the financial markets sector.
Health House has an established pharmacy distribution business in Australia and the UK . Other markets to follow.
Health House is targeting a listing on the ASX in Q2 2021.
Strong Global Industry Relationships
This team have established strong relationships across the globe spanning cultivation, research, clinical trials, medical clinics, e-commerce, animal health and recreational sectors as well as in the capital markets of Canada, Australia and Europe/United Kingdom. Have founded, invested in or advised on multiple companies across the globe.